CNSide Diagnostics is pleased to announce a major milestone in expanding patient access to advanced CNS cancer diagnostics. Humana (NYSE: HUM)—one of the nation’s largest health insurers—has entered into a national agreement with Plus Therapeutics, providing coverage for the CNSide® Cerebrospinal Fluid Tumor Cell Enumeration (TCE) assay. This decision extends potential access to approximately 16 million people across the United States.

With Humana’s policy in place, total coverage for the CNSide® CSF TCE Laboratory Developed Test (LDT) now reaches 67 million lives, marking a significant step forward in improving care for patients with leptomeningeal metastases (LM) and other CNS malignancies.

This coverage expansion reflects the growing recognition of CSF-based tumor cell analysis as an essential tool for detecting and monitoring CNS cancer progression with greater accuracy and clinical utility.

What Humana Coverage Means for Clinicians and Patients

With this agreement, more providers will be able to:

• Access high-quality CSF tumor cell enumeration to assess disease burden
• Monitor LM progression with greater sensitivity than conventional methods
• Support precision-guided treatment planning using objective, quantifiable data
• Reduce financial barriers that often limit patient access to advanced diagnostics

This milestone also reinforces CNSide’s position as a leading platform for precision CNS oncology diagnostics, supporting physicians who manage complex CNS cancers where early detection and accurate monitoring are essential.

Read the Full Press Release

For additional information on Humana’s national coverage determination and the impact of this agreement, please read the official announcement:

Press Release: https://lnkd.in/giMbcEmU

Learn More About CNSide®

CNSide Diagnostics offers a comprehensive CSF assay platform that includes tumor cell enumeration, molecular characterization, advanced imaging, and CEE-Sure CSF Collection Tubes designed to preserve high-quality samples.

Explore the CNSide platform: https://cnside-dx.com

Stay Connected: Join Our Interest List

Be the first to receive updates on new data releases, payer coverage announcements, clinical collaborations, and product enhancements.

Join our Interest List: https://lnkd.in/g6wktSG8